We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
Adma Biologics (ADMA - Free Report) closed at $18.59 in the latest trading session, marking a +1.81% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.13% for the day. On the other hand, the Dow registered a loss of 0.39%, and the technology-centric Nasdaq increased by 0.15%.
Coming into today, shares of the infectious disease drug developer had gained 2.13% in the past month. In that same time, the Medical sector lost 0.96%, while the S&P 500 gained 3.39%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. In that report, analysts expect Adma Biologics to post earnings of $0.14 per share. This would mark year-over-year growth of 7.69%. Simultaneously, our latest consensus estimate expects the revenue to be $121.1 million, showing a 12.98% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.61 per share and revenue of $505.8 million. These totals would mark changes of +24.49% and +18.61%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Adma Biologics has a Forward P/E ratio of 29.93 right now. This expresses a premium compared to the average Forward P/E of 19.79 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 91, placing it within the top 37% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ADMA in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Adma Biologics (ADMA - Free Report) closed at $18.59 in the latest trading session, marking a +1.81% move from the prior day. The stock exceeded the S&P 500, which registered a loss of 0.13% for the day. On the other hand, the Dow registered a loss of 0.39%, and the technology-centric Nasdaq increased by 0.15%.
Coming into today, shares of the infectious disease drug developer had gained 2.13% in the past month. In that same time, the Medical sector lost 0.96%, while the S&P 500 gained 3.39%.
Investors will be eagerly watching for the performance of Adma Biologics in its upcoming earnings disclosure. In that report, analysts expect Adma Biologics to post earnings of $0.14 per share. This would mark year-over-year growth of 7.69%. Simultaneously, our latest consensus estimate expects the revenue to be $121.1 million, showing a 12.98% escalation compared to the year-ago quarter.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $0.61 per share and revenue of $505.8 million. These totals would mark changes of +24.49% and +18.61%, respectively, from last year.
Investors should also pay attention to any latest changes in analyst estimates for Adma Biologics. These latest adjustments often mirror the shifting dynamics of short-term business patterns. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. At present, Adma Biologics boasts a Zacks Rank of #4 (Sell).
Valuation is also important, so investors should note that Adma Biologics has a Forward P/E ratio of 29.93 right now. This expresses a premium compared to the average Forward P/E of 19.79 of its industry.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 91, placing it within the top 37% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ADMA in the coming trading sessions, be sure to utilize Zacks.com.